Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study

Incretins reduce glycemic variability (GV) in patients with type 2 diabetes, but it is unknown whether switching from a combination of basal insulin and a DPP-4 inhibitor to insulin degludec/liraglutide (IDegLira) improves GV. We performed an exploratory prospective observational study to compare th...

Descripción completa

Detalles Bibliográficos
Autores principales: Oe, Yuki, Nomoto, Hiroshi, Nakamura, Akinobu, Kuwabara, Saki, Takahashi, Yuka, Yasui, Ayano, Izumihara, Rimi, Miya, Aika, Kameda, Hiraku, Cho, Kyu Yong, Atsumi, Tatsuya, Miyoshi, Hideaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793345/
https://www.ncbi.nlm.nih.gov/pubmed/35097130
http://dx.doi.org/10.1155/2022/5603864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793345/
https://www.ncbi.nlm.nih.gov/pubmed/35097130
http://dx.doi.org/10.1155/2022/5603864

Ejemplares similares